Evidence map›Paper›PMID 35654312›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2022

Association between Ancestry-Specific 6q25 Variants and Breast Cancer Subtypes in Peruvian Women.

Valentina A Zavala, Sandro Casavilca-Zambrano, Jeannie Navarro-Vásquez, Carlos A Castañeda, Guillermo Valencia, Zaida Morante, Monica Calderón, Julio E Abugattas, Henry Gómez, Hugo A Fuentes and 21 more

Open access · bronzeAbstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Evaluation of Multiple Breast Cancer Polygenic Risk Score Panels in Women of Latin American Heritage.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 10 institutions in 3 countries.

Valentina A ZavalaDepartment of Public Health Sciences, University of California Davis, Davis, California.ORCID 0000-0003-2040-1760
Sandro Casavilca-ZambranoInstituto Nacional de Enfermedades Neoplasicas, Lima, Peru.ORCID 0000-0001-8406-739X
Jeannie Navarro-VásquezInstituto Nacional de Enfermedades Neoplasicas, Lima, Peru.
Carlos A CastañedaInstituto Nacional de Enfermedades Neoplasicas, Lima, Peru.
Guillermo ValenciaInstituto Nacional de Enfermedades Neoplasicas, Lima, Peru.ORCID 0000-0002-4234-4448
Zaida MoranteInstituto Nacional de Enfermedades Neoplasicas, Lima, Peru.ORCID 0000-0003-2952-6068
Monica CalderónInstituto Nacional de Enfermedades Neoplasicas, Lima, Peru.ORCID 0000-0003-4935-7927
Julio E AbugattasInstituto Nacional de Enfermedades Neoplasicas, Lima, Peru.ORCID 0000-0002-9806-0989
Henry GómezInstituto Nacional de Enfermedades Neoplasicas, Lima, Peru.ORCID 0000-0002-3415-9701
Hugo A FuentesInstituto Nacional de Enfermedades Neoplasicas, Lima, Peru.ORCID 0000-0002-2747-7381
Ruddy Liendo-PicoagaInstituto Nacional de Enfermedades Neoplasicas, Lima, Peru.
Jose M CotrinaInstituto Nacional de Enfermedades Neoplasicas, Lima, Peru.
Claudia MongeInstituto Nacional de Enfermedades Neoplasicas, Lima, Peru.
Silvia P NeciosupInstituto Nacional de Enfermedades Neoplasicas, Lima, Peru.ORCID 0000-0002-2657-9853
Scott HuntsmanDivision of General Internal Medicine, Department of Medicine, University of California, San Francisco, San Francisco, California.
Donglei HuDivision of General Internal Medicine, Department of Medicine, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-0351-001X
Sixto E SánchezUniversidad Peruana de Ciencias Aplicadas, Lima, Peru and Asociación Civil Proyectos en Salud (PROESA), Lima, Peru.ORCID 0000-0003-0354-0523
Michelle A WilliamsDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Angel Núñez-MarreroDepartment of Biochemistry, Cancer Biology Division, Ponce Research Institute, Ponce Health Sciences University, Ponce, Puerto Rico.ORCID 0000-0002-5154-9621
Lenin GodoyDepartment of Biochemistry, Cancer Biology Division, Ponce Research Institute, Ponce Health Sciences University, Ponce, Puerto Rico.ORCID 0000-0002-4507-2775
Aaron HechmerHelen Diller Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
Adam B OlshenHelen Diller Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.
Julie DutilDepartment of Biochemistry, Cancer Biology Division, Ponce Research Institute, Ponce Health Sciences University, Ponce, Puerto Rico.
Elad ZivDivision of General Internal Medicine, Department of Medicine, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-2324-2884
Jovanny ZabaletaDepartment of Pediatrics and Stanley S. Scott Cancer Center LSUHSC, New Orleans, Louisiana.ORCID 0000-0002-5961-6761
Bizu GelayeDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Jule VásquezInstituto Nacional de Enfermedades Neoplasicas, Lima, Peru.ORCID 0000-0001-6477-4660
Marco Gálvez-NinoInstituto Nacional de Enfermedades Neoplasicas, Lima, Peru.ORCID 0000-0002-1408-4474
Daniel Enriquez-VeraUniversidad Privada San Juan Bautista, Lima, Peru.ORCID 0000-0002-0855-8936
Tatiana Vidaurre *Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru.ORCID 0000-0003-1995-4560
Laura Fejerman *Department of Public Health Sciences, University of California Davis, Davis, California.ORCID 0000-0003-3179-1151
Instituto Nacional de Enfermedades Neoplásicas · PEPonce Health Sciences University · PRSan Francisco General Hospital · USHarvard University · USUniversity of California, Davis · USPeruvian University of Applied Sciences · PEStanley Foundation · USUCSF Helen Diller Family Comprehensive Cancer Center · USUniversidad Privada San Juan Bautista · PEUniversity of California, San Francisco · US

Funding

A Cohort Study of Preterm Delivery in Relation to Partner Abuse, Mood and AnxietyR01HD059835 · NICHD · UNIVERSITY OF WASHINGTON · PI WILLIAMS, MICHELLE A. · 2010 to 2014
$2.8M
Biological implications of breast cancer protective variants in Latin Americanwomen with high Indigenous American ancestryR01CA204797 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FEJERMAN, LAURA · 2016 to 2020
$1.9M
NCI NIH HHS R01 CA204797NICHD NIH HHS R01 HD059835
6 · The paper itself

Abstract

backgroundBreast cancer incidence in the United States is lower in Hispanic/Latina (H/L) compared with African American/Black or Non-Hispanic White women. An Indigenous American breast cancer-protective germline variant (rs140068132) has been reported near the estrogen receptor 1 gene. This study tests the association of rs140068132 and other polymorphisms in the 6q25 region with subtype-specific breast cancer risk in H/Ls of high Indigenous American ancestry.

methodsGenotypes were obtained for 5,094 Peruvian women with (1,755) and without (3,337) breast cancer. Associations between genotype and overall and subtype-specific risk for the protective variant were tested using logistic regression models and conditional analyses, including other risk-associated polymorphisms in the region.

resultsWe replicated the reported association between rs140068132 and breast cancer risk overall [odds ratio (OR), 0.53; 95% confidence interval (CI), 0.47-0.59], as well as the lower odds of developing hormone receptor negative (HR-) versus HR+ disease (OR, 0.77; 95% CI, 0.61-0.97). Models, including HER2, showed further heterogeneity with reduced odds for HR+HER2+ (OR, 0.68; 95% CI, 0.51-0.92), HR-HER2+ (OR, 0.63; 95% CI, 0.44-0.90) and HR-HER2- (OR, 0.77; 95% CI, 0.56-1.05) compared with HR+HER2-. Inclusion of other risk-associated variants did not change these observations.

conclusionsThe rs140068132 polymorphism is associated with decreased risk of breast cancer in Peruvians and is more protective against HR- and HER2+ diseases independently of other breast cancer-associated variants in the 6q25 region. IMPACT: These results could inform functional analyses to understand the mechanism by which rs140068132-G reduces risk of breast cancer development in a subtype-specific manner. They also illustrate the importance of including diverse individuals in genetic studies.

Indexed as

Breast NeoplasmsChromosomes, Human, Pair 6Erb-b2 Receptor Tyrosine KinasesFemaleHispanic or LatinoHumansLogistic ModelsPeruReceptors, EstrogenReceptors, ProgesteroneErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, Progesterone

Identifiers

PMID35654312
PMCPMC9662925
OpenAlexW4282937736

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.